Table 3 Comparison of Wuhan-like and variant of concerns haemagglutination test responders after one and two doses of mRNA vaccine in younger and older adults, as well as in previously infected individuals with SARS CoV-2.

From: A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern

 

Responders n/N (%)

Virus#

Vaccinated

Infected3

Older1

Younger2

Older1

Younger2

Post 1st dose

Post 2nd dose

Wuhan-like

28/89 (31)

228/309 (74)

70/89 (78)

308/309 (100)

289/307 (94)

Alpha, B.1.1.7

26/89 (29)

177/309 (57)

68/89 (76)

307/309 (99)

284/307 (92)

Beta, B.1.351

18/89 (20)

168/309 (54)

55/89 (62)

298/309 (96)

233/307 (76)

Gamma, P.1

22/89 (25)

171/309 (55)

52/89 (58)

299/309 (97)

209/307 (68)

Delta B.1.617.2

21/89 (24)

204/309 (66)

64/89 (72)

309/309 (100)

253/307 (82)

  1. 189 seronegative older vaccinees 3 weeks after 1st and 3–5 weeks after 2nd dose of mRNA vaccine.
  2. 2309 younger adult vaccinees 3 weeks after 1st and 3–5 weeks after 2nd dose of mRNA vaccine.
  3. 3307 SARS-CoV-2 infected individuals with convalescent sera collected 4–6 weeks after infection.
  4. #The viruses tested are the ancestral virus (Wuhan-like) and variant of concern (B.1.1.7 alpha; B.1.351 beta; P.1 gamma and B.1.617.2 delta) viruses. The data is presented as the subjects with HAT titre over 40 against the different variants, n/N and as percentage (%) of the whole group.
Back to article page